; Peplin Inc. (PEIC) - Financial and Strategic SWOT Analysis Review
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Peplin Inc. (PEIC) - Financial and Strategic SWOT Analysis Review

VIEWS: 27 PAGES: 30

Peplin Inc. (PEIC) - Financial and Strategic SWOT Analysis Review Summary Peplin Inc. (Peplin), formerly known as Peplin Biotech Ltd., is a development-stage, specialty pharmaceutical company. The company is engaged in research, advancing and commercialization of innovative medical dermatology product candidates. It focuses on developing PEP005 (ingenol mebutate), an anti-cancer drug, which is derived from Euphobia peplus, a plant referred to as radium weed or petty spurge, for indications such as actinic (solar) keratosis (AK) and basal cell carcinoma (BCC). PEP005 Gel is useful as a topical, field-directed therapy for AK lesions on both head (face and scalp) and non-head (trunk and extremities) locations. The company operates manufacturing facilities in Southport, Queensland, Australia for API production of its owned proprietary lead compound PEP005 (ingenol mebutate). In 2009, Peplin became a wholly-ownedsubsidiary of LEO Pharma A/S (LEO), a Denmark-based, privately-held pharmaceutical company. Peplin is headquartered at Emeryville in California, the US. This comprehensive SWOT profile of Peplin Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products

More Info
  • pg 1
									            Peplin Inc. (PEIC) - Financial and Strategic SWOT Analysis Review

       Reference Code: GDPH213341FSA                                                                                     Publication Date: MAY 2011

       6475 Christie Avenue, Suite 300 Phone                   +1 510 6539700                       Revenue           NA
       Emeryville, CA                  Fax                     +1 510 6539704                       Net Profit        -43.87 (million USD)
       94608                                 Website           www.peplin.com                       Employees         40
       United States                         Exchange          PEIC [Over The Counter]              Industry          Pharmaceuticals & Healthcare

      Company Overview
       Peplin Inc. (Peplin), formerly known as Peplin Biotech Ltd., is a development-stage, specialty pharmaceutical company. The
       company is engaged in research, advancing and commercialization of innovative medical dermatology product candidates. It
       focuses on developing PEP005 (ingenol mebutate), an anti-cancer drug, which is derived from Euphobia peplus, a plant referred
       to as radium weed or petty spurge, for indications such as actinic (solar) keratosis (AK) and basal cell carcinoma (BCC). PEP005
       Gel is useful as a topical, field-directed therapy for AK lesions on both head (face and scalp) and non-head (trunk and
       extremities) locations.

      Key Executives                                                                 SWOT Analysis
                     Name                                  Title                     Peplin Inc., SWOT Analysis
      Eugene Bauer, M.D.                    Chief Medical Officer                    Strengths                           Weaknesses

      Thomas G. Wiggans                     Chairman
                                                                                                                         Reliance on a Single Source
      Joshua Funder Ph.D.                   Director                                 Expertise In-house Research         Supplier
                                                                                     Activities
      Cherrell Hirst                        Director
                                                                                                                         Increasing Operating
      Gary W Pace, Ph.D.                    Director                                                                     Expenses
                                                                                     Intellectual Property Base
      Source: Annual Report, Company Website, Primary and Secondary Research,
      GlobalData

      Share Data
                                                                                     Opportunities                       Threats
       Peplin Inc.
                                                                            0.0      Leo Pharma’s Acquisition of         Uncertain R&D Outcomes
                                                                                     Peplin
       EPS (USD)                                                          -3.21
                                                                                                                         Increasing Competitive
       Market Cap (million USD)                                             0.0      Market Potential: Cancer            Pressures
       Enterprise Value (million USD)                                       NA

       Shares Outstanding (million)                                             15
       Source: Annual Report, Company Website, Primary and Secondary Research,       Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       GlobalData

      Financial Performance




       Source: Annual Report, Company Website, Primary and Secondary Research,
       GlobalData




Peplin Inc. (PEIC) - Financial and Strategic SWOT Analysis Review                                                               Reference Code: GDPH213341FSA

Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
      Table of Contents
      Table of Contents........................................................................................................................................................................................................... 2
      List of Tables .................................................................................................................................................................................................................. 3
      List of Figures................................................................................................................................................................................................................. 3
      Section 1 - About the Company ..................................................................................................................................................................................... 4
      Peplin Inc. - Key Facts ................................................................................................................................................................................................... 4
      Peplin Inc. - Key Employees .......................................................................................................................................................................................... 5
      Peplin Inc. - Key Employee Biographies ........................................................................................................................................................................ 6
      Peplin Inc. - Major Products and Services ..................................................................................................................................................................... 8
      Peplin Inc. - History ........................................................................................................................................................................................................ 9
      Peplin Inc. - Company Statement ................................................................................................................................................................................ 10
      Peplin Inc. - Locations And Subsidiaries...................................................................................................................................................................... 12
            Head Office............................................................................................................................................................................................................ 12
            Other Locations & Subsidiaries ............................................................................................................................................................................. 12
      Section 2 – Company Analysis .................................................................................................................................................................................... 13
      Peplin Inc. - Business Description................................................................................................................................................................................ 13
      Peplin Inc. - Corporate Strategy................................................................................................................................................................................... 14
      Peplin Inc. - SWOT Analysis ........................................................................................................................................................................................ 15
            SWOT Analysis - Overview ................................................................................................................................................................................... 15
            Peplin Inc. - Strengths ........................................................................................................................................................................................... 15
                  Strength - Expertise In-house Research Activities.......................................................................................................................................... 15
                  Strength - Intellectual Property Base .............................................................................................................................................................. 15
            Peplin Inc. - Weaknesses ...................................................................................................................................................................................... 15
                  Weakness - Reliance on a Single Source Supplier......................................................................................................................................... 15
                  Weakness - Increasing Operating Expenses .................................................................................................................................................. 15
                  Weakness - Deteriorating Profitability Ratios.................................................................................................................................................. 16
            Peplin Inc. - Opportunities ..................................................................................................................................................................................... 16
                  Opportunity - Leo Pharma’s Acquisition of Peplin........................................................................................................................................... 16
                  Opportunity - Market Potential: Cancer........................................................................................................................................................... 16
                  Opportunity - Changing Demographics........................................................................................................................................................... 16
            Peplin Inc. - Threats..............................................................................
								
To top